Alnylam Pharmaceuticals Inc (ALNY)

Industry Biotechnology

This stock can be held in an Investment ISA and an Investment Account

Sell

$308.88

Buy

$357.19

arrow-down$-9.88 (-3.01%)

Prices updated at 02 Apr 2026, 23:32 EDT

Prices minimum 15 mins delay

Prices in USD

Alnylam Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in developing novel therapeutics based on RNA interference, or RNAi. RNAi is a naturally occurring biological pathway within cells for regulating the expression of specific genes.

NASDAQ

0.18%

NASDAQ

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

Our Investment Fees and Charges.

Sector

Healthcare

Industry

Biotechnology

Chairman

Ms. Amy W. Schulman

CEO

Dr. Yvonne L Greenstreet, MB.Ch.B.

Most recent earnings

31 Dec 2025

Fiscal year end

31 Dec 2025

Employees

2,500

Head office

675 West Kendall Street

Cambridge

United States

02142

+1 617 551-8200

INVESTORS@ALNYLAM.COM

Company website

Key personnel

Owner name chevron-l-regular chevron-r-regular	Salary
Dr. Elliott Sigal, M.D.,PhD Independent Director	0.08m
Dr. Margaret A. Hamburg, M.D. Independent Director	0.07m
Dr. Phillip A. Sharp,PhD Independent Director	0.08m
Ms. Amy W. Schulman Chairman of the Board	0.14m
Dr. Yvonne L Greenstreet, MB.Ch.B. Director and Chief Executive Officer	1.25m
Mr. David E.I. Pyott, M.A.,M.B.A. Independent Director	0.08m
Dr. Dennis A. Ausiello, M.D. Independent Director	0.08m
Mr. Peter N. Kellogg Independent Director	-
Dr. Olivier Raymond Brandicourt, M.D. Independent Director	0.08m
Mr. Stuart A. Arbuckle Independent Director	-
Mr. Jeffrey V. Poulton Executive Vice President, Chief Financial Officer and Principal Accounting Officer	0.69m
Ms. Colleen F. Reitan Independent Director	0.09m
Dr. Pushkal P. Garg, M.D. Chief Medical Officer and Executive Vice President, Development and Medical Affairs	0.68m
Mr. Tolga Tanguler Chief Commercial Officer	0.63m
Mr. Kevin Joseph Fitzgerald, PhD Executive Vice President, Chief Scientific Officer and Head, Early Research and Early Development	0.59m

Top 5 shareholders

Owner name chevron-l-regular chevron-r-regular	No. of shares
Capital Research and Management Company	22,377,451
Capital Group	18,412,485
Capital World Investors	16,301,772
FMR Inc	15,902,149
Fidelity Management and Research Company	15,902,149

Director dealings

Date chevron-l-regular chevron-r-regular	Action
26 Nov 2025	-
26 Nov 2025	-
26 Nov 2025	-
26 Nov 2025	-
26 Nov 2025	-
26 Nov 2025	-
26 Nov 2025	-
26 Nov 2025	-
26 Nov 2025	-
17 Nov 2025	-
17 Nov 2025	-
17 Nov 2025	-
17 Nov 2025	-
17 Nov 2025	-
17 Nov 2025	-
17 Nov 2025	-
17 Nov 2025	-
17 Nov 2025	-
17 Nov 2025	-
17 Nov 2025	-

Please note that past performance is not a reliable indicator of future returns.

Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.